You are here

Article Text

Article menu
Download PDFPDF
DTB select
EMA suspends licence for ingenol mebutate (Picato)

Abstract

Overview of: Medicines and Healthcare products Regulatory Agency. Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Drug Safety Update 2020;13(7):1.

  • adherence
  • adverse effects

https://doi.org/10.1136/dtb.2020.000012

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.